Want to see TSE:SONA full AI Analyst Report?
SONA Stock Chart & Stats
C$0.40
>-C$0.01(-2.00%)
At close: 4:00 PM EST
C$0.40
>-C$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeC$0.26 - C$0.84
Previous CloseN/A
Volume36.80K
Average Volume (3M)124.26K
Market Cap
C$40.03M
Enterprise ValueC$32.88M
Total Cash (Recent Filing)C$52.76K
Total Debt (Recent Filing)C$328.87K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding114,375,250
10 Day Avg. Volume87,178
30 Day Avg. Volume124,263
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Nanorod TechnologySona's core focus on proprietary gold nanorod materials and related assay applications is a durable strategic asset. Ownership of differentiated labeling/contrast technology targets diagnostics and life-science workflows, providing a clear product-led route to commercial partnerships and recurring reagent demand if adoption scales.
Reduced Cash Burn Vs. PeakManagement has materially lowered losses and cash consumption versus the 2021 peak, which lengthens runway and reduces near-term financing pressure. This structural improvement increases the time available to validate products, pursue partnerships, or reach initial commercialization milestones without immediate insolvency risk.
Low Absolute Debt BurdenTotal debt is modest in absolute terms (~329K TTM), limiting fixed-interest obligations. For a cash-burning pre-revenue company, low nominal debt preserves financial flexibility and reduces short-term default risk, making capital raises less constrained by existing creditors and easing negotiations with potential partners.
Bears Say
No Commercial RevenueThe company reports no revenue across recent periods and a TTM net loss near $2.7M, indicating lack of commercial traction. Without demonstrated sales, product-market fit and recurring demand remain unproven, forcing reliance on financing and creating structural uncertainty about long-term viability absent successful commercialization.
Negative Shareholder EquityShareholders' equity has moved negative, raising balance-sheet and solvency concerns. Negative equity weakens borrowing capacity, increases dilution risk when financing is required, and can deter commercial partners or larger customers, creating persistent structural headwinds to funding growth or executing long-term contracts.
Persistent Cash Burn And Worsening FCFOperating cash flow remains negative (~-1.26M TTM) and free cash flow has deteriorated (~-39% decline), signaling accelerating cash consumption. This structural cash deficit forces recurring capital raises or severe cost cuts, increasing dilution risk, distracting management from commercialization, and compressing the time window to achieve self-sustaining operations.
Sona Nanotech Inc News
SONA FAQ
What was Sona Nanotech Inc’s price range in the past 12 months?
Sona Nanotech Inc lowest stock price was C$0.26 and its highest was C$0.84 in the past 12 months.
What is Sona Nanotech Inc’s market cap?
Sona Nanotech Inc’s market cap is C$40.03M.
When is Sona Nanotech Inc’s upcoming earnings report date?
Sona Nanotech Inc’s upcoming earnings report date is Sep 24, 2026 which is in 67 days.
How were Sona Nanotech Inc’s earnings last quarter?
Sona Nanotech Inc released its earnings results on Jun 29, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
Is Sona Nanotech Inc overvalued?
According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued.
Does Sona Nanotech Inc pay dividends?
Sona Nanotech Inc does not currently pay dividends.
What is Sona Nanotech Inc’s EPS estimate?
Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sona Nanotech Inc have?
Sona Nanotech Inc has 114,375,250 shares outstanding.
What happened to Sona Nanotech Inc’s price movement after its last earnings report?
Sona Nanotech Inc reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sona Nanotech Inc?
Currently, no hedge funds are holding shares in TSE:SONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sona Nanotech Inc
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.
Technical Analysis
BioMark Diagnostics
―
Eastwood Bio-Medical Canada
―
StageZero Life Sciences Ltd
―
Medmira
―
ZYUS Life Sciences
―